Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PCV24 in Adults
NCT06678607Phase 1Completed
- Sponsor
- Shanghai Reinovax Biologics Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Reinovax PCV24 in pneumococcal infection (4 arms), sponsored by Shanghai Reinovax Biologics Co., Ltd. Primary endpoint: Incidence of adverse reactions. Started Nov 2023; status: completed.
02
Drugs
Reinovax PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06678607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678607.